Cardlytics (NASDAQ:CDLX) Upgraded to Strong-Buy by Northland Capmk

Cardlytics (NASDAQ:CDLX) was upgraded by equities research analysts at Northland Capmk to a “strong-buy” rating in a research report issued on Tuesday, Zacks.com reports.

CDLX has been the subject of a number of other reports. Lake Street Capital raised their price target on Cardlytics from $13.00 to $18.00 and gave the stock a “buy” rating in a research note on Friday, March 15th. Needham & Company LLC reissued a “buy” rating and set a $12.00 price target on shares of Cardlytics in a research note on Tuesday, June 11th. Craig Hallum decreased their price target on Cardlytics from $18.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, May 9th. Finally, Northland Securities assumed coverage on Cardlytics in a report on Tuesday. They set an “outperform” rating and a $14.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Cardlytics has an average rating of “Buy” and a consensus price target of $13.00.

Cardlytics Price Performance

NASDAQ:CDLX opened at $8.21 on Tuesday. The firm has a market capitalization of $400.24 million, a price-to-earnings ratio of -1.86 and a beta of 1.67. Cardlytics has a 1 year low of $5.53 and a 1 year high of $20.52. The business has a 50 day simple moving average of $10.75 and a 200-day simple moving average of $9.58. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.13 and a quick ratio of 2.13.

Cardlytics (NASDAQ:CDLX) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.35) earnings per share (EPS) for the quarter. Cardlytics had a negative return on equity of 25.36% and a negative net margin of 55.23%. The business had revenue of $67.61 million for the quarter.

Insiders Place Their Bets

In other news, major shareholder Clifford Sosin acquired 225,000 shares of Cardlytics stock in a transaction on Thursday, May 9th. The shares were bought at an average cost of $8.73 per share, for a total transaction of $1,964,250.00. Following the acquisition, the insider now directly owns 6,361,113 shares of the company’s stock, valued at approximately $55,532,516.49. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CEO Karim Saad Temsamani sold 43,129 shares of Cardlytics stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $8.65, for a total value of $373,065.85. Following the transaction, the chief executive officer now directly owns 385,530 shares in the company, valued at approximately $3,334,834.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Clifford Sosin purchased 225,000 shares of the business’s stock in a transaction dated Thursday, May 9th. The stock was bought at an average price of $8.73 per share, for a total transaction of $1,964,250.00. Following the completion of the acquisition, the insider now directly owns 6,361,113 shares in the company, valued at approximately $55,532,516.49. The disclosure for this purchase can be found here. Insiders have sold 79,435 shares of company stock worth $828,269 in the last ninety days. 4.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Kent Lake Capital LLC purchased a new position in Cardlytics during the 1st quarter worth $3,622,000. Blackstone Inc. purchased a new position in Cardlytics during the 1st quarter worth $2,029,000. Perbak Capital Partners LLP purchased a new position in Cardlytics during the 1st quarter worth $2,348,000. Price T Rowe Associates Inc. MD grew its stake in Cardlytics by 6.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 29,769 shares of the company’s stock worth $432,000 after buying an additional 1,774 shares during the last quarter. Finally, Quadrature Capital Ltd purchased a new position in Cardlytics during the 1st quarter worth $1,906,000. 68.10% of the stock is currently owned by hedge funds and other institutional investors.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.